Safety, Efficacy, and Exposure‑Response of NNZ‑2591, a Synthetic Analog of Cyclic Glycine‑Proline (cGP), an IGF‑1 Metabolite, for the Treatment of Phelan‑McDermid Syndrome in Children and Adolescents
Your question will be sent privately to Neuren Pharmaceuticals. The company may choose to make this question public.
Start the conversation
Ask Neuren Pharmaceuticals a question about this update.
